natgillin/translations-raw huggingface dataset:
The obtained solution is evaporated in vacuum at 40–50° C. Acetone or acetonitrile is added to the formed mass (what predominantly is viscous syrup), and the mixture is grated. 
Dobivenu otopinu se ispari u vakuumu pri 40-50%C. U nastalu masu (koja je pretežno u obliku viskoznog sirupa) doda se aceton ili acetonitril i smjesu se protrlja.
wherein X in (VI) represents hydroxy or a leaving group; which reaction is an O-arylation reaction wherein X represents a leaving group, or a Mitsunobu reaction, wherein X is hydroxy; 
A q ii s pri čemu X u (VI) predstavlja hidroksi ili izlaznu skupinu, a koja reakcija posebice je O-arilacijska reakcija pri 10
A method for altering, destroying or eliminating target cells in an animal by i) administering a nanoparticle or nanoparticle aggregate or a composition comprising the nanoparticle or nanoparticle aggregate, wherein the nanoparticle or nanoparticle aggregate consists of a metal oxide coated with a biocompatible coating, wherein the density of the nanoparticle or the density of the nanoparticle aggregate is at least 7 g/cm3, and the nanoparticle or nanoparticle aggregate is covered with a biocompatible coating providing the nanoparticle or the nanoparticle aggregate stability between pH 6.5 and 7.5 in a physiological fluid, and ii) exposing said animal to ionizing radiations. 
HR P20181993 T1 PATENTNI ZAHTJEVI Uporaba nanočestica HfO, ili agregata nanočestica HfO, za pripremu farmaceutskog pripravka za uporabu u postupku mijenjanja ili uništavanja ciljnih stanica u životinje kada su spomenute stanice izložene ionizirajućim zračenjima, pri čemu je gustoća spomenutih nanočestica HfO, ili gustoća spomenutih agregata nanočestica HfO, barem 7 g/cm', i pri čemu je svaka nanočestica ili agregat nanočestica obložen biokompatibilnom ovojnicom koja daje nanočestici ili agregatu nanočestica stabilnost između pH 6,5 1 7,5 u fiziološkoj tekućini.
a is an integer from 0 to 3; 
je a cijeli broj od 0 do 3;
The practical experiments (see examples below) have found that it is expedient for the water-suspended microparticulate calcite mineral at a concentration of 15 g/L water to have a zeta potential in the range from +10 mV to −10 mV, the surfactant being one that can be shift the zeta potential of the water-suspended microparticulate calcite mineral to a value of at least −20 mV or less, i.e., values lying even further in the negative range. 
0,1 % do 5 % tenzida, gdje je tenzid anionski tenzid ili smjesa anionskih tenzida, i gdje mikropartikulirani mineral kalcit suspendiran u vodi u koncentraciji od 15 g/l voda ima zeta potencijal u rasponu od +10 mV do -10 mV, gdje je anionski tenzid onaj koji može pomaknuti zeta potencijal mikropartikuliranog minerala kalcita suspendiranog u vodi do vrijednosti od najmanje -20 mY ili manje.
The pharmaceutical composition according to claim 1, comprising at least two peptides, wherein said peptides comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 10, or SEQ ID NO: 12 to SEQ ID NO: 23; provided that the composition comprises at least one peptide comprising SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 12 or SEQ ID NO: 13 or salt thereof; and further comprising mannitol and poloxamer 188, wherein the ratio by weight of peptides to mannitol to poloxamer 188 ranges is in the range including and between 1:5:1.5 to 1:8:2.2. 
Farmaceutski sastav prema zahtjevu 1, koji se sastoji od najmanje dva peptida, gdje spomenuti peptidi sadrže slijed aminokiselina odabranih iz skupina koje se sastoje od ID br. baz.: 1 do ID br. baz.: 10, ili ID br. baz.: 12 do ID br. baz.: 23; pod uvjetom da sastav sadrži najmanje jedan peptid koji uključuje ID br. baz.:1, ID br. baz.: 2, ID br. baz.: 12 ili ID br. baz.: 13 ili njihove soli koje dalje sadrže manitol i poloksamer 188, gdje je omjer prema težini peptida prema manitolu prema poloksameru 188 u rasponu uključujući i između 1:5:15 do 1:8:2.2.
Figure 3 illustrates the effect of Isomer A (3-30 mg/kg, p.o.) 
Slika 3 prikazuje učinak Izomera A (3-30 mg/kg, p.o.)
In one embodiment, the expansion medium comprises EGF, a Wnt agonist, FGF, and Nicotinamide. 
Nikotinamid, i Wnt agonist koji je izabran od Rspondin 1, Rspondin 2, Rspondin 3 ili Rspondin 4.
H, alkyl group such as a methyl or ethyl group, olefinic or aromatic or may specifically be: 
H, alkil skupina kao što je metil ili etil skupina, olefinska ili aromatska skupina ili može posebno biti: zombi
hydrocolloid 1-10% The substrate may be impregnated with the composition to the extent that the ingredients penetrate at least the surface layer of the substrate or preferably impregnate the bulk of the substrate structure. 
Postupak za proizvodnju prehrambenog proizvoda prema patentnom zahtjevu 1 ili 2, naznačen time što je supstrat impregniran kompozicijom stabilizatora prije oblaganja sa kompozicijom vodenog omotača.
In a further aspect there is provided the polymorph in pure form. 
U daljnjem aspektu osigurava se polimorf u čistom obliku.
reacting a compound of formula wherein X1 is halogen with a compound of formula to form a compound of formula wherein the definitions are as described in claim 1, or, if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts. 
[image] gdje X1 je halogen, sa spojem sljedeće formule 2: [image] za tvorbu spoja formule I: [image] pri čemu su definicije opisane u zahtjevu 1, ili ako se želi, pretvaranje dobivenih spojeva u farmaceutski prihvatljive kiselinske adicijske soli.
The shelf according to claim 1, wherein a first portion and/or a second portion of the strip extends along and/or in a first side and/or a second side of the plate. 
Polica (10) sukladno patentnom zahtjevu 1, pri čemu dio (26) trake (21) produžuje duž i/ili u bočnu stranu ploče (11).
The compound of Example 1 was hydrolyzed in liver S9 of all species described. 
Spoj iz Primjera 1 hidrolizira se u S9 jetara svih opisanih vrsta.
The valve according to claim 1, wherein the passageway of the valve member comprises, in the flow direction, a first part extending from the inlet of the passageway towards the rotational axis, and a second part extending coaxially with the rotational axis from a radially inner end of the first part towards the channel outlet opening. 
Ventil prema bilo kojem od prethodnih Zahtjeva, gdje prolaz elementa ventila sadrži, promatrano u smjeru protoka, prvi dio (320a; 321a) koji se pruža od dovoda (322) prolaza prema osi rotacije i drugom dijelu (320b; 321b) koji se pruža koaksijalno s osi rotacije iz radijalno unutarnjeg kraja prvog dijela (320a; 321a) prema otvoru kanala odvoda.
A pharmaceutical composition comprising (a) a cyclopolysaccharide, and (b) a compound of Formula (I) or a pharmaceutically acceptable salt thereof: wherein 
HR P20180690 T1 PATENTNI ZAHTJEVI Farmaceutski sastav sadržeći (a) ciklični polisaharid, te (b) spoj Formule (II):
Concentrator according to anyone of claim 19 to 21, further adapted to perform the operation of transmitting a start time and an end time to the remote meter (RM) requesting transmission of consumption related data from said start time to said end time. 
Sabirnik prema patentnom zahtjevu 19 do 21, koji je nadalje prilagođen za provođenje operacija prijenosa vremena početka 1 završetka u daljinski brojač (RM) zahtijevajući prijenos podataka vezanih uz potrošnju od navedenog vremena početka do završetka,
Such beverage bottles contain only small volumes, such as a few litres, and are not directly comparable to metal kegs which hold a substantially larger volume of beverage. 
Takove boce za piće sadrže samo male volumene, kao na primjer nekoliko litara, i one se ne mogu izravno usporediti s metalnim bačvama u kojima se drži uglavnom veći volumen pića.
The compound of any one of claims 1-18 for use in a method of modulating a CSF1R, FLT3, KIT, and/or PDGFRB kinase. 
Tvar iz bilo kojeg od patentnih zahtjeva 1-18 za uporabu u metodi moduliranja CSFIR, FLT3, KIT i/ili PDGFRp kinaze.
An object of the disclosure is the chimeric protein encoded by the nucleic acid constructs as described herein above, comprising at least one operatively linked invariant chain or variants thereof and at least one antigenic protein or peptide or fragment of said antigenic protein or peptide. 
Nukleinska kiselina kao konstrukt, naznačena time što sadrži sljedove koji kodiraju a. - najmanje jednu varijantu nepromjenjivog lanca operativno vezanu na b. najmanje jedan antigenski protein ili peptid ili antigenski fragment navedenog proteina ili peptida, gdje najmanje jedna varijanta nepromjenjivog lanca sadrži samo:
The method according to claim 1 comprising releasing the working fluid into the hole near a toe of the hole to enable mixing of the working fluid and the flushing fluid in the hole. 
Postupak prema zahtjevu 9, koji sadrži oslobađanje radnog fluida (34) u rupu u blizini dna bušotine kako bi se omogućilo miješanje radnog fluida (34) i fluida (36) za ispiranje unutar bušotine.
The single immunoglobulin variable domain antibody of claim 1 that is formatted to increase its in vivo half-life. 
Antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu iz zahtjeva 1, naznačeno time, što se formatira tako da mu se produži in vivo poluživot.
providing a container (1), 
osiguravanje posude (1), -
The system according to claim 10, further comprising a controller controlling the imaging device and the at least one illuminating device based on feedback from the image processing device. 
Sustav prema jednom od zahtjeva 5-7, naznačen time da nadalje sadrži nadzorni uređaj koji kontrolira uređaj za snimanje (12) i uređaj za osvjetljavanje (16) na temelju povratne informacije od uređaja za obradu slike.
467nm from a xenon lamp, or 488nm from an argon lamp, both of which are remote from wavelengths that are absorbed by the analyte) and/or using suitable filters (e.g. 
467 nm iz ksenonske svjetiljke ili 488nm iz argonske svjetiljke, koje su udaljene od valnih duljina koje analizirana tvar apsorbira) i/ili koristeći prikladne filtere (na pr.
The motorized rescue buoy of claim 1, wherein the buoy is configured to be launched by dropping the buoy from a height of at least 20 feet. 
Motorizirana bova prema zahtjevu 1, naznačena time, da je bova oblikovana tako, da _se može spustiti u vodu pomoću izbacivanja bove s visine od najmanje 20 stopa.
The particle contrast agent composition can further include a fixing agent selected from the group consisting of gluteraldehyde and formaldehyde. In one embodiment, the permeabilizing agent can be saponin present in amounts sufficient to result in concentrations between about 50 mg/L and about 750 mg/L under staining conditions. 
Pripravak prema zahtjevu 1, naznačen time da: sredstvo za permeabilizaciju je saponin prisutan u dovoljnoj količini da se dobiju koncentracije između oko 50 mg/L i oko 750 mg/L u uvjetima bojenja; i sredstvo za fiksiranje je glutaraldehid prisutan u dovoljnoj količini da se dobiju koncentracije od ili ispod 0.1% u uvjetima bojenja.
Nucleic acids may be inserted into a nucleic acid construct in which expression of the nucleic acid is influenced or regulated by an “expression control element,” referred to herein as an “expression cassette.” 
Molekula nukleinske kiseline koja kodira himerni peptid sukladno bilo kojem od zahtjeva 1 do 9, pri čemu molekula nukleinske kiseline nadalje sadrži element za kontrolu ekspresije u operativnom povezivanju koji daje
methanethiol, phosphor organic compounds such as methylphosphine, dimethylphosphine; their derivatives and mixtures thereof. 
metantiol, organski spojevi fosfora kao što su metilfosfin, dimetilfosfin; njihovi derivati i njihove smjese.
f)—Extending supporting legs down to a road surface; 
spuštanje potpornih nogu (12, 12a-12c) na površini ceste (FBD);
In that situation, particular importance is attached to the possibility of the remission also of infectious pathologies which are not widespread but which are of considerable socio-epidemiological importance, such as bacillary dysentery and pseudomembranous colitis, and also of infectious complications in surgical operations at the expense of the large intestine and in particular the colon. 
U tom slučaju posebno je važno razmotriti i mogućnost remisije infektivnih patoloških stanja koja nisu jako rasprostranjena ali imaju značajnu socio-epidemiološku važnost, kao što su bacilarna dizenterija i pseudomembranski kolitis, te također infektivne komplikacije prilikom kirurških operacija na uštrb debelog crijeva posebno kolona.
The process of claim 2, wherein the step of formulating the material comprises adding an excipient. The process of claim 2 or claim 3, wherein: 
Postupak prema zahtjevu 2, naznačen time, da korak formuliranja materijala obuhvaća dodavanje pomoćnog sredstva.
R1, R2, and R3 are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkynyl, cyano, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, nitro, NRARB, and (NRARB)carbonyl; 
Ri, R2, 1 Ra su neovisno odabrani iz skupine koja se sastoji od vodika, alkenila, alkoksi, alkoksikarbonila, alkila, alkinila, cijano, haloalkoksi, haloalkila, halogena, hidroksi, hidroksialkila, nitro, NRARsg i (NRaARs)karbonila;
This invention relates to a pharmaceutical combination for the treatment of spasticity and/or pain. 
Ovaj izum se odnosi na farmaceutsku kombinaciju za liječenje grčeva i/ili boli.
The GRPR-antagonist as claimed in any one of the claims 1-5, wherein the metal chelator C is a metal chelator for technetium or rhenium. 
Radiomarkirani GRPR-antagonist prema zahtjevu 1, pri čemu je metalni kelator C metalni kelator za tehnecij ili renij.
is NRN5RN6 where RN5 and RN6 together with the nitrogen to which they are bound form an optionally substituted imidazolyl, morpholino, thiomorpholino, piperadinyl, homopiperadinyl, piperazinyl, homopiperazinyl or pyrrolidinyl, wherein optional N-substituents on the piperazinyl and homopiperazinyl groups are selected from C1-7alkyl and ester, and optional C-substituents for the imidazolyl, morpholino, thiomorpholino, piperadinyl, homopiperadinyl, piperazinyl, homopiperazinyl or pyrrolidinyl groups are selected from phenyl, ester, amide and C1-4 alkyl. 
je NRN5RN6 gdje RN5 i RN6 zajedno s dušikom na koji su oni vezani tvore proizvoljno supstituiranu skupinu imidazolil, morfolino, tiomorfolino, piperadinil, homopiperadinil, piperazinil, homopiperazinil ili pirolidinil, pri čemu su proizvoljni N-supstituenti na skupinama piperazinil i homopiperazinil odabrani od C1-7alkila i estera, te su proizvoljni C-supstituenti za skupine imidazolil, morfolino, tiomorfolino, piperadinil, homopiperadinil, piperazinil, homopiperazinil ili pirolidinil odabrani od fenila, estera, amida i C1-4 alkila.
is benzyl, cycloalkyl, arylcycloalkyl, adamantyl, aryl or heterocyclyl, wherein benzyl, cycloalkyl, arylcycloalkyl, aryl and heterocyclyl are optionally substituted with one to three substituents independently selected from alkyl, cycloalkyl, alkoxy, hydroxy, halogen, trifluormethyl, trifluoromethoxy, benzyl, phenyl and phenyl substituted with one to three substituents independently selected from alkyl, alkoxy, hydroxy, cycloalkyl, halogen and trifluoromethyl; 
R* je benzil, cikloalkil, arilcikloalkil, adamantil, aril ili heterociklil, gdje benzil, cikloalkil, arilcikioalkil, aril i heterociklil su po izboru supstituirani jednim do tri supstituenta neovisno odabranima od alkila, cikloalkila, alkoksi, hidroksi, halogena, trifluormetila, trifluorometoksi, benzila, fenila, a fenil je supstituiran jednim do tri supstituenta neovisno odabranima od alkila, alkoksi, hidroksi, cikloalkila, halogena i trifluorometila;
separating the alcoholic-caustic phase containing the trans-(-)-A9-tetrahydrocannabinol or the trans-(+)-A9-tetrahydrocannabinol from the first organic phase; 
separaciju trans-(-)-A9-tetrahidrokanabinola i trans-(+)-A9-tetrahidrokanabinola od alkoholno-kaustične faze; i
This application claims priority to U.S. Serial No. 60/490,407, filed on July 25, 2003 . 
Ova prijava zahtijeva pravo prioriteta dokumenta U. S. Serial No. 60/490,407, zaprimljenog 25. srpnja 2003.
The composition of any of claims 1-4, further comprising a second therapeutic agent useful in the treatment or prevention of a disease or condition selected from emotional lability; pseudobulbar affect; autism; neurological disorders; neurodegenerative diseases; brain injury; disturbances of consciousness disorders; cardiovascular diseases; glaucoma; tardive dyskinesia; diabetic neuropathy; retinopathic diseases; diseases or disorders caused by homocysteine-induced apoptosis; diseases or disorders caused by elevated levels of homocysteine; chronic pain; intractable pain; neuropathic pain; sympathetically mediated pain; pain associated with gastrointestinal dysfunction; epileptic seizures; tinnitus; sexual dysfunction; intractable coughing; dermatitis; addiction disorders; Rett syndrome (RTT); voice disorders due to uncontrolled laryngeal muscle spasms; methotrexate neurotoxicity; and fatigue caused by cancer. 
Smjesa prema zahtjevu 3 ili 4, ili zahtjevima 5-8 kada ovise o zahtjevu 3 ili 4, koja dalje sadrži drugo terapijsko sredstvo korisno u liječenju ili prevenciji bolesti ili stanja izabranih između; emocionalna nestabilnost; pseudobulbarni afekt; autizam; neurološki poremećaji; neurodegenerativne bolesti; ozljeda mozga; poremećaji svijesti; kardiovaskularne bolesti; glaukom; tardivna diskimezija; dijabetička neuropatija; retinopatijske bolesti; bolesti ili poremećaji uzrokovani apoptozom koja je inducirana homocisteinom; bolesti ili poremećaji uzrokovani povišenim razinama homocisteina; kronična bol; intraktabilna bol; neuropatska bol; bol posredovana simpatikusom; bol povezana s disfunkcijom probavnog sustava; cpiloptički napadaji; tinitus; seksualna disfunkcija; intraktabilni kašalj; dermatitis; poremećaji ovisnosti; Rettov sindrom (RTT); poremećaji glasa uslijed nekontroliranog grčenja mišića larinksa; neurotoksičnost metotreksata; i umor uzrokovan rakom.
The method of paragraph 41, wherein the binding agent is present in an amount ranging from about 0.01 wt% to about 50 wt% of the second formulation, preferably from about 0.01 wt% to about 10 wt% of the second formulation. 
Postupak prema zahtjevu 34, naznačen time da je sredstvo za vezanje prisutno u količini koja je u opsegu od 0,01 mas.% do 50 mas.% druge formulacije, poželjno od 0,01 mas.% do 10 mas.% druge formulacije.
Lower temperature during baking process and bake last 10 minutes at 160 °C. 
Potom tijekom pečenja sniziti temperaturu na 160" C i peći još 10 minuta.
The Na+-salt is especially preferred for the preparation of liquid pharmaceutical formulations, e.g. 
Na"- sol je naročito prvenstvena za proizvodnju tekućih farmaceutskih formulacija, npr.
The process of claim 55, wherein said base is selected from the group consisting of organic, inorganic, and organometallic bases. 
Postupak u skladu s patentnim zahtjevom 55, naznačen time što navedenu bazu se bira iz skupine koju čine organske, anorganske i organometalne baze.
Complete substitution results in zero set off after approximately 40 seconds for coated as well as calendered papers. Printing sheet for offset printing, comprising at least one image receiving coating and optionally one or several pre-coatings beneath said image receiving coating, said coatings comprising a pigment part, a binder part, and optionally additives, wherein the pigment part essentially comprises one or a mixture of fine particulate pigments selected from the group of carbonate, kaolin, gypsum, clay, silica, solid or vacuolated polymer pigment, wherein said binder part comprises waterglass, characterized in that the weight ratio of SiO2:Na2O in the waterglass is above or equal to 3.2. 
List papira za offset tisak, koji se sastoji od najmanje jednog premaza koji prima sliku i proizvoljno jednog ili nekoliko prethodnih-premaza ispod navedenog premaza koji prima sliku, te navedeni premazi sadrže pigmentni dio, vezivni dio, i proizvoljno aditive, pri čemu pigmentni dio u osnovi sadrži jedan pigment ili mješavinu sitnih čestica pigmenata odabranu iz skupine karbonata, kaolina, gipsa, gline, silicij-dioksida, krutog polimernog pigmenta ili koji sadrži sitne šupljine, pri čemu navedeni vezivni dio sadrži vodeno staklo, naznačen time da je težinski omjer SiO,:Na,0 u vodenom staklu veći ili jednak 3.2.
where X is halogen; the reduction of a compound of formula II to give a compound of formula 
St) gdje je X halogen; b. redukciju spoja formule II da se dobije spoj formule
VLA is linked with VHB by a first linker L1, VHB is linked with VLB by a second linker L2 and VLB is linked with VHA by a third linker L3; 
VLA je vezana za VHB prvim linkerom L1, VHB je vezana za VLB drugim linkerom L2 i VLB je vezana za VHA trećim linkerom L3;
The composition of claim 3, wherein the mutant Spy0416 antigen comprises at least one amino acid substitution selected from the group consisting of D151A and S617A. 
Pripravak u skladu s patentnim zahtjevom 3, naznačen time što antigen iz mutanta Spy0416 ima najmanje jednu aminokiselinsku zamjenu koju se bira iz skupine koju čine DI5IA i S617A.
incorporating said polymeric side stream possibly together with the expanding agent, in a second polymeric stream, or main polymeric stream, containing vinyl aromatic polymers and/or vinyl aromatic copolymers in the molten state, thus forming the self-extinguishing expandable composition. 
dodavanja navedene polimerne bočne struje, moguće zajedno sa sredstvom za ekspandiranje, u drugu polimernu struju, ili glavnu polimernu struju, koja sadrži vinilaromatske polimere i/ili vinilaromatske kopolimere u rastaljenom stanju, čime se dobije samougasiva ekspandabilna mješavina.
To this regard the evacuation outlet openings (and thus the drip trays 41, 42) are at a lower position than the inlet sides of the thermoblocks to be evacuated. 
S tim u vezi otvori na izlazu za pražnjenje (a time i korita za prikupljanje kapi 41 i 42) nalaze se niže od ulaznih strana termoblokova koje se prazni.
The method of claim 1, wherein the pharmaceutical composition is administered at a frequency of one to four administrations per day. 
Farmaceutska dozna formulacija za upotrebu prema patentnom zahtjevu 12, naznačena time što se farmaceutska formulacija administrira sa frekvencijom od jedne do četiri administracije dnevno.
The system of claim 13 wherein biasing electrodes includes one or more of one or more point electrodes positioned within the containment chamber to contact open field lines, a set of annular electrodes between the confinement chamber and the first and second formation sections to charge far-edge flux layers in an azimuthally symmetric fashion, a plurality of concentric stacked electrodes positioned in the first and second divertors to charge multiple concentric flux layers, and anodes of the plasma guns to intercept open flux. 
HR P20190738 T1 slojeva toka na udaljenim bridovima na azimutno simetričan način, mnoštvo koncentrično naslaganih elektroda koje su pozicionirane u prvom i drugom preusmjerivaču, u svrhu punjenja nabojem višestrukih koncentričnih slojeva toka, te anode od plazma-pištolja u svrhu da se prepriječi otvoreni tok (452).
Following the 3 minute habituation period, the rats are given two 3 minute trials (T1 and T2) which are separated by a 1 minute inter-trial interval in the home cage during which the objects are changed. 
Nakon razdoblja 3 minute privikavanja, štakorima su zadana dva tri minutna pokusa (TI 1 T2) koja su bila odijeljena s jedno-minutnim među-pokusnim razdobljem u osnovnom kavezu za vrijeme kojeg su zamijenjeni predmeti.
As regards said calcium carbonate-comprising material in suspension, this material preferably comprises at least 50%, preferably of at least 80%, and more preferably of at least 98%, by weight of calcium carbonate relative to the total equivalent dry weight of said calcium carbonate-comprising material. 
Uporaba u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakterizirana na način da navedeni materijal koji sadrži kalcijev karbonat sadrži najmanje 50 %, poželjno najmanje 80 % i poželjnije najmanje 98 %, po težini kalcijevog karbonata u odnosu na ukupnu težinu navedenog materijala koji sadrži kalcijev karbonat.